MedTrace Logo

CHAPTER: Clonal Haematopoiesis Assessment: Prevention, Treatment and Research

NCT07313059 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-05-13

No results posted yet for this study

Summary

People identified to have CH or thought to have possible CH due to unexplained low blood cell counts, including low red blood cells, white blood cells, or platelets will be asked to take part in the study.

Individuals who are confirmed to have CH and provide informed consent to participate in the study will have monitoring of their CH, assessment of the risk of heart diseases, blood cancers and personalised support. The researchers will also measure people's understanding of CH and how they feel after learning about CH.

Researchers will then record the relevant information from people with CH in a central database over time to track long-term health outcomes.

The information collected from the study will help create a blueprint for doctors to provide care for people with CH in the future, and guide further research into CH in Australia.

Participants will be asked to donate blood samples for the study for research purposes including CH monitoring and testing and also provide health information for the central database.

Conditions

  • Clonal Hematopoiesis
  • CCUS Clonal Cytopenia of Undetermined Significance
  • Hematologic Disease and Disorders

Sponsors & Collaborators

  • Medical Research Future Fund

    collaborator OTHER

  • Australian National University

    collaborator OTHER

  • University of Auckland, New Zealand

    collaborator OTHER

  • The Canberra Hospital

    collaborator OTHER

  • Clinical Hub for Interventional Research (CHOIR)

    lead OTHER_GOV

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-20
Primary Completion
2033-11-30
Completion
2033-11-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07313059 on ClinicalTrials.gov